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ABSTRACT

Author: Wasilczuk, Kelsey, M. MSBME
Institution: Purdue University
Degree Received: May 2018
Title: Low Intensity Focused Ultrasound Stimulation of the Vagus Nerve for Modulation of the
Inflammatory Reflex Assessed in Rats
Major Professor: Pedro Irazoqui

Major depressive disorder (MDD) affects approximately 300 million people globally,
with over 15% having treatment-resistant depression (TRD). People with depression have
elevated levels of pro-inflammatory cytokines, especially tumor necrosis factor alpha (TNF-α).
Electrical vagus nerve stimulation (eVNS) is an alternative treatment option that works by
reducing cytokine production, but requires surgery and isn’t always effective. As an alternative, I
propose the use of focused ultrasound stimulation of the vagus nerve (fVNS), which can be
applied non-invasively. Low intensity focused ultrasound stimulation has previously been used
to stimulate structures in the brain and peripheral nerves such as the sciatic and abducens.
However, it has not been used to excite the vagus nerve. In this study, my colleagues and I used
an LPS challenge in rats to induce an inflammatory response. I applied one or three 5-minute
pulsed focused ultrasound stimulations to the vagus nerve (250 kHz, ISPPA= 3 W/cm2) and
collected blood to analyze the effects of fVNS therapy on cytokine concentrations. Animals that
received a single ultrasound application saw an average decrease in TNF-α levels by 19%,
similar to electrically stimulated animals, which decreased on average by 16% compared to the
control. With multiple applications, fVNS therapy statistically reduced serum TNF-α levels
(73% reduction) compared to control animals without any observed damage to the nerve. When I
cauterized the vagus nerve, the stimulation no longer had a reduction effect on TNF-α. These
findings indicate that focused ultrasound stimulation can excite the vagus nerve and has the
potential for use as a non-invasive, lower risk therapy for TRD.
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1. INTRODUCTION

1.1

Cytokine Theory of Depression
Major Depressive Disorder (MDD) is a wide-spread disease, affecting over 300 million

people globally[1]. Depression can cause impairment in daily activities at home, work, in
relationships, and in social settings[2]. In the United States, prevalence of lifetime MDD is about
35 million adults, affecting about 16% of the population at some point in life[2]. In this group,
15% of people with MDD develop treatment-resistant or refractory depression[3]. It is difficult
to reliably determine the best drug for a patient, as only approximately 50% of patients go into
remission after receiving drugs from two different classes. Even following four treatment steps
(varying combinations of drugs and dosages with or without cognitive therapy), only 67% of
patients achieve remission[4]. It is also important to note that in some studies greater than 50%
reduction in symptoms on the Hamilton Depression Rating Scale (HAM-D) or the MontgomeryAsberg Depression Rating Scale (MADRS) can be characterized as remission, even though
patients beginning with severe depression may still experience symptoms[5]. Therefore, it is
important to consider measurements such as relapse or remission rates when evaluating a therapy
for depression. In addition, pharmaceutical treatment of depression comes with side effects such
as nausea and sexual dysfunction[6]. For these reasons, we need to find alternative ways to treat
depression as well as learn more about the causes of depression.
Cytokines are small proteins that are important for cell signaling, typically produced by
immune cells. There are two main classes – pro-inflammatory, such as tumor necrosis factor
alpha (TNF-α), and anti-inflammatory, such as IL-10. The cytokine theory of depression
hypothesizes that the overproduction of cytokines (and lack of anti-inflammatory cytokines)
causes depressive symptoms. More specifically, studies link high levels of the cytokine TNF-α
to depression[7, 8]. In one study, high serum concentrations of TNF-α correlated with a lack of
response to the medication escitalopram, implicating cytokines further as a factor in treatmentresistant depression[8]. Therefore, if we reduce pro-inflammatory cytokines in the body using the
inflammatory reflex circuitry, we have the potential to treat these depressive symptoms.
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1.2

The Inflammatory Reflex
Neural regulation of the immune response is fast and integrated, unlike typical pathways,

which rely on concentration gradients that are relatively slow[9]. The vagus nerve, which is the
tenth cranial nerve and termed the “wandering nerve” is believed to be involved in the immune
system by regulating cytokines through the inflammatory reflex. The afferent fibers of the vagus
nerve transmit signals to the brain, which results in responsive efferent fiber signaling. This
efferent vagus nerve signaling activates T cells that release Acetylcholine (ACh) once taken up
by the spleen. Then, ACh interacts with α7 subunits of nicotinic receptors, causing them to
release noradrenaline. These α7 receptors have been found to be essential in attenuation of
cytokine release through VNS[10]. Noradrenaline then interacts with beta adrenergic receptors
on splenic macrophages leading to the deactivation and inhibition of cytokines[9]. This pathway
is shown in Figure 1. The spleen plays an important role in both the production and suppression
of cytokines. Removal of the spleen results in the reduction of TNF-α in response to systemic
LPS[11]; however, splenectomy in humans results in immunodeficiency and heightens the risk
for lethal bacterial infections, making it impractical for the clinical treatment of depression[12].

Figure 1: Vagus nerve stimulation sends efferent fiber signals to the vagal target, which
mobilizes T-cells.[13] When the spleen uptakes them, T-cells release acetylcholine (ACh), which
interacts with the α subunits of nicotinic receptors present in the sympathetic terminals. These
receptors release noradrenaline (NA), interacting with the beta-adrenergic subunits on the
macrophages to suppress the release of TNF-α. TNF-α is increased in production by LPS.
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A common model for studies of depression and sepsis is injecting lipopolysaccharides
from Escherichia Coli (LPS) to cause an inflammatory response. With the injection of LPS,
circulating LPS Binding Protein (LBP) recognizes LPS in the plasma and brings it to CD14.
CD14 assists in the loading of LPS into the receptor complex composed of dimerized toll-like
receptor 4 (TLR4) and 2 lymphocyte antigen 96 proteins (MD-2s). This activates three different
pathways, including the NF-κB pathway, leading to the expression of pro-inflammatory
cytokines[14].

1.3

Current Treatments for Depression
Typically, pharmaceuticals are the first form of treatment for depression. The majority of

pharmaceuticals aim to increase levels of monoamines, such as serotonin, norepinephrine, and
dopamine, as the monoamine hypothesis of depression suggests that people with depression
display deficiencies in these monoamines[5]. There are a variety of drugs that can be prescribed,
but the most common fall into one of the following categories: selective serotonin reuptake
inhibitors (SSRIs), tricyclic antidepressants (TCAs), serotonin norepinephrine reuptake inhibitors
(SNRIs), and monoamine oxidase inhibitors (MAOIs)[5]. Typically SSRIs and SNRIs are the
first line of treatment, but are not always effective even after four different treatment steps[4]. In
addition, time to achieve antidepressant effects can take weeks, in part because of the once daily
oral dosing[15]. Because of the downsides of pharmaceutical treatments and the prevalence of
treatment-resistant depression, patients need non-pharmaceutical options. Vagus nerve
stimulation (VNS), repetitive transcranial magnetic stimulation (rTMS), and electroconvulsive
therapy (ECT) are all FDA approved alternatives to tradition pharmaceutical methods for
patients with treatment-resistant depression.
Using a high current pulse generator and coils, rTMS stimulates neural targets in the
brain. While clinical trials have proven the effectivity of rTMS, the neural target, parameters for
stimulation, and timing of stimulations to achieve continued remission remain unanswered. The
FDA approved rTMS for the treatment of depression in October 2008[16]. It’s difficult to
compare the effectiveness between rTMS and antidepressants or electroconvulsive therapy
because of the difficulty in performing a blind study (patients undergo anesthesia for ECT, but
not for rTMS). Studies comparing the therapies included few subjects and mostly saw no
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difference between treatment groups. However, the study revealed that people with depression
with psychotic features should not receive rTMS[16]. Although rTMS could be an effective
treatment in combination with antidepressants, the spacial acuity of rTMS is in the centimeter
range and requires a trip to the doctor or hospital for the treatment. It is yet to be determined how
often patients must return for treatment for continued antidepressant effects, so it is difficult to
assess how in-office treatments could influence a patient’s daily life.
ECT is a treatment carried out on an anesthetized patient in which small currents pass into
the brain via electrodes to induce seizures (Figure 2). This therapy has been around since the
1930s but has changed significantly over that period of time. In clinical studies, it appears that
ECT can be significantly more effective than sham ECT or pharmacological therapy; however,
the long-term efficacy of ECT is unclear[17]. A recent study in Turkey showed only a 34%
sustained remission rate after 1 year of follow-up[18]. Although this is lower than most studies
have shown, it could be because of the longer follow-up period used in their study compared to
others[18]. Overall, while seemingly effective, the therapy has several downsides including the
patient needing to be anesthetized, short-term amnesia, and possible ineffectiveness as a longterm treatment[17].

Figure 2: Electroconvulsive therapy application is shown with current being passed into the brain
via two electrodes[19].
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VNS consists of implanting a cuff around the cervical vagus nerve and placing a
stimulator subcutaneously to pass electrical current through the nerve to generate action
potentials (Figure 3). The FDA approved VNS in 1997 for the treatment of refractory
epilepsy[20]. However, after epilepsy patients showed relief of depressive symptoms even with
no decrease in their seizures, researchers investigated using VNS for the treatment of depression.
In 2005, the FDA approved VNS for use in chronic TRD[20]. Side effects of VNS include
hoarseness, cough, dyspnea, neck pain, and headache, experienced to various degrees usually
during stimulation[21]. While VNS implantation is a relatively low-risk surgery, possible
complications include vocal cord paralysis, migration of the pulse generator, and lead
failure[22]. In addition, MRI of the neck or spine is contraindicated after implantation[21]. After
going through the surgery, patients may not achieve remission. In a recent 5 year follow up study
of 795 patients divided into VNS or treatment-as-usual groups, 43.3% and 25.7% of VNS and
treatment-as-usual patients, respectively, achieved remission[23]. Although VNS achieved
statistically higher remission rates, it did not result in significantly longer durations of remission
(although the durations were on average longer)[23]. Their results show that that over half of
patients implanted with a VNS device will not see remission, and if they do achieve remission, it
may not last.

Figure 3: Typical placement of a VNS device, with the electrodes placed on the vagus nerve in
the neck[24].
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1.4

Focused Ultrasound Background
To overcome the shortcomings of current treatments for TRD, we explored improving

vagus nerve stimulation by using focused ultrasound stimulation instead of electrical stimulation.
Focused ultrasound is an emerging method for non-invasive therapy, where a transducer emits
ultrasonic waves and focuses them to a single point, called the focus or focal point (Figure 4).
The ultrasonic waves only produce an effect at the focal point, leaving tissues surrounding the
target undamaged. Typically, magnetic resonance imaging (MRI) or ultrasound imaging
identifies the target area for focused ultrasound treatment. Focused ultrasound therapies range
from beginning stage research to clinically approved therapies, with applications in nearly every
system in the body. There are two general treatment categories for focused ultrasound – high
intensity focused ultrasound (HIFU) and low-intensity focused ultrasound (LIFU).
HIFU ablates tissue through cavitation and thermal effects using high frequency
transducers at high intensities, typically greater than 200 W/cm2 [25, 26]. Fry was the first to
look at focused ultrasound for ablation to destroy localized regions of tissue[27, 28]. HIFU
applied to peripheral nerves ceases action potentials causing permanent or reversible changes
with possible applications for pain or spasticity relief[29-32]. Clinically, HIFU aids in drug
delivery and cardiac pacing as well as treatment of essential tremor and treatment-refractory
obsessive-compulsive disorder[33-36]. In addition to its ability to ablate tumors, research
recently shows immunomodulation as an added benefit of focused ultrasound tumor ablation in
humans[37-39].
Low intensity focused ultrasound (LIFU) mechanically stimulates tissues without
damaging them and can stimulate brain tissue, disrupt the blood brain barrier, and stimulate
peripheral nerves[40]. Transducer frequencies are typically less than 1 MHz and less than 20
W/cm2 in intensity. The first studies with LIFU happened in the 1950s, discovering effects of
ultrasound that were unexplainable by thermal mechanisms[41-43]. Later, Gavrilov applied
LIFU to human hands to determine any sensations felt during stimulation[44]. More recently,
researchers show LIFU to successfully stimulate neural circuits and peripheral nerves for in vivo
transcranial applications[45-50]. Studies show the ability to either stimulate or suppress neural
activity depending on the input parameters. However, parameters vary widely between neural
and peripheral nerve stimulation as well as between species.
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Figure 4: Curved transducer aligns the sound waves into a focal region, where the intensity is the
highest.

1.5

Mechanisms of Action for Focused Ultrasound of Neural Tissue
Although LIFU is gaining traction in research, the mechanism by which it works is still

largely undefined. There are four main hypotheses for how focused ultrasound may work –
thermal mechanisms, cavitation, cell membrane changes, or opening of mechanosensitive ion
channels[51]. Most experiments similar in intensity to ours do not elicit enough heat for thermal
mechanisms to be at work and are under the threshold for cavitation. In addition, cavitation is
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more likely to occur in areas where there is natural gas (such as the lungs or intestines) or with
injected microbubbles[25]. The mechanosensitive ion channels hypothesis has gained the most
traction, and has been observed experimentally with potassium (K+), sodium (Na+), and calcium
(Ca2+) channels[51-54]. Ion channels previously deemed “voltage-gated” ion channels are
typically also mechanically sensitive[55]. In fact, Oschs and colleagues applied a mechanical
stress to rat sciatic nerves and caused either an increase or decrease in compound action potential,
comparable to the suppression and stimulation of neural targets observed with focused
ultrasound[56]. Furthermore, researchers are trying to develop models for how focused
ultrasound incorporates into accepted models for electrical generation of an action potential.
These models include the soliton model, neuronal intramembrane cavitation excitation (NICE)
model, and the flexoelectricity hypothesis[57]. For example, the NICE model integrates a nonconstant membrane capacitance into the Hodgkin-Huxley model to help account for action
potentials due to focused ultrasound[57].

1.6

Characterization of Therapy Parameters
The wide range of input parameters for focused ultrasound provides flexibility for its

extensive list of applications. These parameters that impact the beam’s intensity includes the
transducer’s resonating frequency, input sine wave, and continuous versus pulsed application.
Two common ways to communicate intensity over the application period is spatial peak temporal
average intensity (ISPTA) and spatial peak pulsed average intensity (ISPPA). ISPTA corresponds to
the intensity over the full pulse repetition period, including when the beam is off, whereas ISPPA
only averages the intensity over the time the beam is on (Figure 5). A hydrophone measures the
pressure wave output by the focused ultrasound transducer. We can measure the output signal
from the hydrophone with an oscilloscope and use the following equations to calculate the
intensity of the stimulation (Equations 1 – 5).
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Where P is the pressure amplitude (Pa), Vpp is the peak-to-peak voltage as seen on the
oscilloscope (V), gain is the gain of the hydrophone (dB), OVC is the sensitivity of the
hydrophone (V/Pa), I is the instantaneous intensity (W/cm2), Z is the acoustic impedance of the
medium (kg/ms2), DC is the duty cycle (ms), and PRP is the pulse repetition period (s)[58-60].

Figure 5: Illustrations of the common ways to describe intensity of focused ultrasound beams.
The most common that are addressed in this these are spatial peak, temporal average and pulse
average, all illustrated here[61].
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1.7

Research Goals
Based on the successful stimulation of other nerves in the body using focused ultrasound,

we hypothesized that the left vagus nerve could be similarly stimulated. We investigated the use
of focused ultrasound as a new therapy for refractory depression by using an LPS model of
depression in rats. We assessed the effectiveness of focused ultrasound stimulation in attenuating
serum TNF-α levels compared with electrically stimulated animals and looked at the effects of
multiple applications of focused ultrasound.
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2. MATERIALS AND METHODS

The Purdue Animal Care and Use Committee (PACUC) approved all protocols in this study.
We used 39 Sprague-Dawley rats weighing between 185 and 450 g. We housed animals in
standard conditions with ad-libitum access to food and water.

2.1

Animal Groups
We divided animals into five groups – no stimulation with LPS (nVNS, n=11), one

ultrasound stimulation with LPS (f1VNS, n=11), three ultrasound stimulations with LPS (f3VNS,
n=8), three ultrasound stimulations with LPS and efferent fiber vagotomy (f3Vx, n = 4), and
electrical stimulation with LPS (eVNS, n=5). In initial experiments, we took six blood
collections total, but transitioned to twelve blood collections to see the full TNF-α response
curve. Animal numbers for each collected time point can be seen in Table 1.

Table 1: Number of animals per group divided into the specific time points of the experiment
nVNS

f1VNS

f3VNS

f3Vx

Blood Collections

1–6

7 – 12

1–6

7 – 12

1–6

7 – 12

1-7

8

9-12

Animals In Group

11

5

11

5

10

5

4

3

2

2.2

Surgery
We anesthetized rats using 4-5% isoflurane for approximately 3 minutes. After weighing,

we injected rats intraperitoneally (IP) with a ketamine/xylazine (ket/xyl) cocktail consisting of
75mg/kg ketamine and 5mg/kg xylazine. We administered buprenorphine (0.07cc, SC) or
butorphanol (0.04 cc, SC) as an analgesic. Anesthesia was maintained with IP injections of
ket/xyl every thirty minutes, or as needed based on toe pinch and heart rate. We applied artificial
tears to the animal’s eyes and shaved and cleaned the incision sites. We placed the animal supine
on a heating pad and placed it under oxygen flowing at 2L/min for the remainder of the
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experiment. At the completion of the last blood collection, I euthanized the animals via a lethal
dose of Beuthanasia-D Special (0.9cc, IP).
Although focused ultrasound can be applied non-invasively, I exposed the vagus nerve in
order to ensure the acoustic focus of the ultrasound transducer had consistent positioning. To
expose the left cervical vagus nerve, I made the initial incision beginning at the midline of the
jaw, moving caudally. I exposed the soft tissue until the sternohyoid and sternocleidomastoid
muscles, which sit on top of the carotid sheath, were visible. I carefully dissected the carotid
sheath until the left vagus nerve was completely free from surrounding tissues. For animals
receiving focused ultrasound, I placed two pieces of needleless suture under the vagus nerve in
order to keep it exposed for later application of therapy. For animals receiving electrical
stimulation, I placed a cuff electrode under the vagus nerve, and tied the suture attached to the
cuff to secure the nerve in place. For animals in the f3Vx group, I tied a piece of 6’0 silk suture
tightly around the nerve, as distal as accessible to avoid the efferent fibers of the nerve being
stimulated later. I, then, cauterized the nerve. The suture prevented retraction so that I could later
locate the cranial portion of the nerve for stimulation. We kept the area wet with saline and
covered with gauze for the duration of the surgery when stimulation was not being applied. I
divided control animals to either receive a cuff electrode or needleless suture.

2.3

Blood Collection Methods
We collected up to 12 blood samples with the timeline of the experiment shown in Figure

6. The twelve blood collections occurred every thirty minutes with the exception of the second
blood collection, which took place after one hour. I injected the LPS (5mg/kg, IP) thirty minutes
after the first sample. The first two blood collections served as baseline readings. For blood
collection, we either used leg puncture into heparinized minivettes, catheter into heparinized
tubes, or catheter into 8mm vials containing K3EDTA anticoagulant using the Culex Automatic
Blood Collection System. Jesse Somann, Gabriel Albors, or I inserted the catheter into the left
femoral artery. We flushed the catheter every 10-20 minutes with heparinized saline to prevent
blood clots from forming.
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We processed the blood in batches of two, centrifuging for 10 minutes at 2000 x g. We
used a 250 µL pipette to extract the plasma from the red blood cells and white blood cells. Blood
samples were kept in a frozen tray to keep the samples cold during the experiments. Once we had
six samples, we aliquoted them into 20 µL samples and stored them at -20°C until they could be
processed.

Figure 6: This experimental timeline shows the timing of the blood collections relative to the
LPS injection. Animals receiving stimulation either had stimulation only after blood collection 2,
or after blood collections 2, 4, and 6.

2.4

LPS Preparation/Administration
I either measured LPS individually using a scale or pre-mixed and froze LPS. To make

the pre-mixed LPS, we systematically mixed a new 100 mg bottle of LPS lyophilized powder
with 20 mL of sterile saline (0.9% sodium chloride) and sonicated in batches for 45 minutes total.
We then aliquoted ~400 µL of solution into 1.5 mL eppendorf tubes before freezing and storing
them at -20°C until used. Pre-mixed LPS was only stored for 6 months, according to
manufacturer guidelines. LPS was sonicated for a minimum of 30 minutes prior to injection.

2.5

Ultrasound Stimulation
Before each experiment, I tested the ultrasound transducer in a water bath. I filled the H-

115 transducer with de-gassed, de-ionized water and secured it with a latex covering. I removed
all bubbles from the housing, and checked the coupling cone again immediately prior to
stimulation. To ensure a consistent positioning of the transducer over the vagus nerve, Kelsey
Bayer, David McMillan, and I worked together to manufacture a positioning rod the length of the
ultrasound focus. About five minutes prior to stimulation, I mounted it on a stereotactic frame,

12
positioned it so that it pointed to the vagus nerve, and recorded the coordinates (Figure 7a). I
then replaced the positioning rod with the transducer for stimulation (Figure 7b). I heated
ultrasound gel in a water bath, and then used it to couple the transducer housing and the nerve.

Figure 7: a) The positioning rod is located over the vagus nerve. After this, the coordinates are
recorded, so that I know where to set-up the transducer. b) The focused ultrasound transducer
placed over the rat for application of stimulation.

I applied focused ultrasound stimulation for 5 minutes, to mimic electrical stimulation,
using a function generator with a 250 kHz, 2Vpp sine wave with pulse width of 4 ms and pulse
repetition frequency of 10 Hz. A power amplifier, set up with a gain of 20 dB, amplified the
signal from the function generator, which then fed into the matching network and into the
ultrasound transducer (Figure 8). The waveform and block diagram for connection can be seen in
Figure 9. Stimulation occurred immediately following the second blood collection for f1VNS
animals and after the second, fourth, and sixth blood collections for f3VNS animals.

13

Figure 8: The focused ultrasound system we used for all experiments including the matching
network, transducer, and amplifier.

Figure 9: The waveform that is put into the amplifier is a 2 Vpp sine wave with a frequency of
250 kHz. The sine wave has a pulse width (PW) of 4 ms and pulse repetition frequency (PRF) of
10 Hz. Below is a block diagram showing the connections to set-up the transducer.
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2.6

Stimulation Characterization
Kelsey Bayer and I used the TC4038 Reson hydrophone in water to determine the

intensity at and around the focus of the transducer. The transducer has a cigar-shaped focal
region, with a focal width of 6.045 mm and focal length of 39.49 mm. To generally characterize
the transducer, we measured the pressure wave in 2mm increments at 8 different distances from
the transducer (Figure 10).
To get a more accurate measurement at the exact distance where we are applying the
therapy, we attached the positioning rod to aim at the hydrophone and replaced the positioning
rod with the transducer. We then characterized the pressure wave at that specific location.

Figure 10: The focused ultrasound transducer in a water bath to measure its intensity. The
hydrophone is connected to a pre-amplifier, connected into an oscilloscope. The hydrophone is
moved in 1 or 2 mm increments to generally characterize the focal region.
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2.7

Electrical Stimulation
We fabricated custom-made bipolar electrodes in house using Platinum-Iridium wire and

medical grade silicon tubing, as done previously (Somann et al 2017). Each electrode used a
single strand of wire. Cuffs used for the left cervical vagus had a 0.03” inner diameter and builtin sutures that I tied to enclose the nerve in the cuff (Figure 11). The measured impedance of the
cervical cuff electrodes was 1.40 – 1.62 kΩ at 1kHz.
We used an improved version of the Bionode stimulator, developed by Somann and Dan
Pederson, for all acute stimulation experiments. The constant current stimulator produces chargebalanced, bi-phasic, square wave pulses up to 1.1 mA amplitude. We added a direct current
(DC)-blocking capacitor to prevent current from passing to the animal and circuitry to short the
capacitor between stimulation pulses to prevent charge build-up.
Somann spearheaded the electrical stimulation profiles and verified them before and
during each experiment using an oscilloscope. We used constant current stimulation profiles of
1mA and 200 µs in duration, with a PRF of 5 Hz (Figure 12). This reflected past experiments
seen on the cervical vagus nerve, where successful stimulation took place (Huston et al 2006,
Patel et al 2017, Rosas-Ballina et al 2011). Cervical stimulations revealed voltage amplitudes
ranging from 3.24 V – 3.93 V, resulting in relative interface impedances of 3.24 kΩ – 3.93 kΩ.

Figure 11: Cuff electrode for the electrical vagus nerve stimulation contains built-in suture to
enclose the nerve in the cuff.
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Figure 12: Stimulation profiles from the oscilloscope that show clear, biphasic waveforms with a
200 µs pulse and 5 Hz pulse repetition frequency (PRF).

2.8

Histology
We performed histology on the vagus nerve in preliminary experiments for signs of acute

damage in select animals. I dissected out the left vagus nerve following the sixth blood collection
and fixed in 10% Neutral Buffered solution for 2–7 days. The Histology Research Laboratory
embedded the nerve and surrounding tissue in paraffin, sectioned into 5 µm thick sections, and
stained with hematoxylin and eosin (H&E). A board certified pathologist observed all sections
microscopically.
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2.9

Temperature
When using LIFU, it’s imperative that no damage occurs to the nerve upon mechanical

stimulation due to heating. However, because of the size of the vagus nerve, we found it
impractical to track heating throughout the experiment accurately. Thus, I conducted a bench top
experiment to measure increases in temperature during 5 minutes of ultrasound stimulation at our
parameters of interest. For the bench top experiment, I followed the same experimental timeline
for the f3VNS group. I set up a thermistor connected to a breadboard circuit with an Arduino to
record temperature changes over the experiment. To prevent the thermistor from shorting, I
coated the two leads of the thermistor with silicone tubing. I mounted the positioning rod on the
stereotactic frame and aimed it at the thermistor (Figure 13a). Then, I replaced the positioning
rod with the ultrasound transducer, placing the heated ultrasound gel over the thermistor for
coupling (Figure 13b). In addition, I ran other trials of single stimulation ultrasound application.

Figure 13: a) The positioning rod was used to locate the focused ultrasound application to the
thermistor in the same way the focused ultrasound transducer was located over the nerve. b) The
focused ultrasound transducer replaced the positioning rod for stimulation.
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2.10 Plasma Processing
Jennifer Sturgis and Kathy Ragheb performed all the plasma processing described here.
LEGENDplexTM Rat Th Cytokine Panel (13-plex) analyzed the plasma samples, allowing for the
simultaneous analysis of 13 cytokines: IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, IL-17A, IL-17F,
IL-22, GM-CSF, IFN-γ, and TNF-α.
Plates either were run using the standard 96-well plate method or modified for use with
384 well filter plates. For the 384 well plates, we used a volume of 7.8 µL and with the exception
of the wash steps, we added reagents using an E1-ClipTimTM Electronic Adjustable Tip Spacing
Multichannel Equalizer pipette (2-125 µL). We diluted plasma aliquots 4-fold with assay buffer.
We prepared serial dilutions of the standard at 1.5 times the manufacturer’s suggested highest
concentrations. A 24 point serial dilution of this standard was then prepared with a dilution factor
of 1.5. For each plate, we added the standard in duplicate on the top and bottom rows of the plate.
We added matrix C and assay buffer to wells containing standards and samples, respectively.
We added beads to all wells and incubated the plate at room temperature with shaking at
2400 rpm on a Bioshake 300 T-elm for 2 hours. We washed plates three times using a
MultiScreen HTS Vacuum Manifold and a Titertek Multidrop 384 Reagent Dispenser to add 75
µL of wash buffer to each well. After washing, 7.8 µL of biotinylated detection antibody solution
was added to each well and the plates were placed on the plate shaker in the dark for 60 minutes.
After this, we added 7.8 µL of the streptavidin-phycoerythrin solution and incubated at room
temperature in the dark on the plate shaker for 30 minutes. We washed the plates 3 times as
previously described, 75 µL of wash buffer was dispensed into all wells, and the plate was placed
on the shaker for 5 minutes at 1600 rpm to remove all beads from the filter. We transferred the
contents of each plate to a V-bottom 384 well plate, adding 35 µL of wash buffer to have a total
volume of 105 µL in each well. The Attune 14 color cytometer equipped with an autosampler
read the plates by collecting 5000 beads per well and exported the data as standard FCS files.
Upon completion of each plate, MPLEX software analyzed the FCS files. The software
opened all 384 listmode files, and upon identification of the bead signal (APC) and the detection
signal (PE), it collected a 2-parameter plot with APC on the x-axis and forward scatter on the yaxis to resolve the 13 populations of beads. Each cytokine was then identified by its preset bead
size and dye intensity level. There were six intensity levels for the smaller A beads and seven
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intensity levels for the larger B beads. We identified the standard curves by their location on the
384 well plates and identified duplicates. The MPLEX software was preset for a Legendplex
assay profile, which associated the beads with the appropriate cytokine. An automated clustering
algorithm was used to fit the bead populations to the pre-designated beads, and the standard
curves for all 13 cytokines were automatically calculated, followed by production of a CSV
output file with all well data[62].

2.11 Statistical Analysis
I detected outliers using interquartile range (IQR), which is a robust method of outlier
removal. Points lying outside of 1.5 times the IQR below or above the first or third quartile,
respectively, were removed from statistical analysis. I then used MATLAB R2015a to perform
the statistical analysis using the ttest2 and anova1 functions.
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3. RESULTS

3.1

Cytokine Results

Although we performed a 13-cytokine panel, we only saw statistically significant, consistent
effects on serum TNF-α levels with stimulation. Overall, the f3Vx group showed the highest
TNF-α levels followed by the no stimulation control group (nVNS). The eVNS and f1VNS
groups had a very similar reduction in TNF-α compared to nVNS, although not statistically
significant. The f3VNS group had significantly lower TNF-α levels compared with the nVNS
group.
ANOVA showed statistical differences between groups at t=90 and t=120. The f1VNS and
f3VNS groups are the same up until t=90, after which the second stimulation occurs for the
f3VNS group, thus they do not show statistical difference at t=90 (p=0.79). Animals that received
vagotomies showed a statistical increase in serum TNF-α levels from the rest of the groups at
t=90 and t=120. There is a statistical difference between the nVNS group and f3VNS group at
t=120 (p=0.04) and TNF-α values remain lower throughout the rest of the experiment (Figure
14). The decrease in serum TNF-α levels is similar for eVNS and f1VNS animals compared to
the control (Figure 15).
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Figure 14: TNF- alpha response curve for animals receiving no stimulation or triple stimulation.
Vagotomized animals (f3Vx, n=4) had a statistically significant increase in concentration at t=90
and t=120. Animals in the f3VNS group (n=11) had a statistically lower concentration at t=120
than nVNS (n=11) and remained lower throughout the remainder of the experiments. Error bars,
s.e.m.

Figure 15: Plot shows the average serum TNF-α levels for single stimulation and no stimulation
animals. Both electrical stimulation and focused ultrasound stimulation on average decrease
serum TNF-α levels; however, without any further manipulation to the nerve it is not a statistical
decrease. Error bars, s.e.m.
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Comparing the various experimental methods for blood collection and LPS storage, there was no
statistical difference between the two groups. In addition, we found no relationship between the
heart rate or dosage of ket/xyl during the experiment with the TNF-α response curves.
We eliminated three outliers from the above analysis, as described in Section 2.11. Two of these
outlier animals had to be resuscitated during the experiment, which could explain their high
levels of TNF-α. For further explanation of outliers, refer to Section 4.3.

3.2

Intensity Specification
The intensity region for the H-115 transducer was between 4 – 6mm in diameter, which

aligns with the manufacturer’s description. The intensity maps at different heights above the
transducer can be seen in Figure 16.
In addition, we measured the specific intensity for where the vagus nerve is positioned
under the device. The ISPPA and ISPTA that we are applying to the vagus nerve are 3 W/cm2 and
1.2 W/cm2, respectively. As we made our positioning rod to be at the stronger part of the focal
region, we understand why it is higher than other points in the intensity map.
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Figure 16: Each intensity map represents the intensity values at a different heights in z away
from the transducer between 5 – 35 mm. Intensity values are represented in W/cm2. The focal
region is between 4 – 6 mm in size, which matches with the manufacturer’s description.
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3.3

Histology

In order to check for signs of damage to the vagus nerve from the focused ultrasound stimulation
(especially that which may be due to heat generated), the H&E stained vagus nerve samples
underwent examination by a board certified pathologist, who was blinded to the experimental
conditions of each specimen. We performed histology on 8 specimens from the 6 collection
experiments (f1VNS: n = 3; f3VNS: n = 2, nVNS: n = 3). Among the 8 nerve samples, few
neutrophils multifocally infiltrated the perineurium of one rat indicating a mild inflammatory
response with no clinical significance to the animal’s health. All other samples were within
normal limits. An example of an H&E stained sample of the vagus nerve can be seen in Figure
17. These findings did not show any pattern in damage following focused ultrasound stimulation.

Figure 17: H&E stained vagus nerve from an animal receiving f3VNS therapy assessed at six
blood collections. Cells show normal staining and the section is continuous. The perineurum is
present surrounding the nerve. Bar represents 500 µm.

3.4

Temperature

Overall, there was a mean temperature increase of 1.9°C. The temperature returned to the
baseline temperature following the application of focused ultrasound. The temperature increased
between 1.2°C and 2.6°C. Five trials of temperature recording can be seen in Figure 18.
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Figure 18: Temperature recording for five 5-minute applications of low intensity focused
ultrasound.
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4. DISCUSSION

4.1

Major Findings
We found that repeated application of focused ultrasound to the vagus nerve statistically

reduces serum TNF-α levels. To our knowledge, we are the first to see results indicative of the
activation of the vagus nerve with LIFU alone. Prior work indicated that an action potential
could not be generated by focused ultrasound stimulation of the vagus nerve alone and that LIFU
inhibited the action potentials when combined with electrical stimulation[63]. To date, there are
no recorded observations of the generation of action potentials in vivo. Therefore, we used serum
cytokine concentrations to measure successful stimulation instead. fVNS eliminates the need for
surgical intervention, which should make it more affordable and lower risk than traditional eVNS.
The ability to manipulate several parameters to control the intensity of stimulation could allow
for more flexibility to reduce side effects, while keeping the therapy effective. In addition, with
recent evidence that chronic cuffing of the vagus nerve in rats leads to efferent fiber damage, we
could prevent consequences of cuffing over long periods of time including scar formation and
the possibility of compromising nerve function[62].
The presence or absence of a vagotomy heavily influenced the TNF-α response.
Vagotomized animals had significantly higher levels of TNF-α throughout the experiment,
consistent with other literature[64, 65]. Animals received three applications of ultrasound cranial
to the vagotomy, activating only afferent fibers. Without the efferent fibers, focused ultrasound
did not reduce TNF-α levels as we expected since the inflammatory reflex relies on efferent
vagus nerve fibers. Therefore, I believe we are activating the inflammatory reflex similarly to
eVNS. In addition, this shows that the reduction in TNF-α levels is not a result of the stimulation
of surrounding tissues and structures.

4.2

Stimulation Parameters
The parameters for focused ultrasound significantly affect the results of its stimulation, as

shown by Yoo and colleagues, where varying focused ultrasound parameters in rabbits led either
to suppression or stimulation of neural structures[66]. We found a lower intensity (3 W/cm2) to
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achieve stimulation than Kim and colleagues’ stimulation of the abducens nerve, possibly
because of our longer sonication time. Our PRF (10Hz) was higher than Kim et al’s study, but
the same as Yoo et al’s study as well as a popular frequency for clinical eVNS[65-67]. Our
transducer frequency of 250 kHz is in the typical range for neurostimulation studies, but we used
a shorter duty cycle (4ms).
In future studies, we should determine the lowest ISPPA and ISPTA to elicit attenuation of
TNF-α, similar to previous studies[67]. Ultrasound repeatedly demonstrates as an all-or-nothing
phenomenon, so lowering the intensity will be unlikely to impact the reduction in TNF-α
levels[50, 67]. Others have performed parametric studies to optimize parameters for transcranial
focused ultrasound, and similar experiments should be conducted on the vagus nerve[50, 68].

4.3

Mechanisms of Action
The underlying mechanism of nervous system activation and suppression with focused

ultrasound is still unclear. One common hypothesis is that voltage-gated ion channels can also be
mechanosensitive, allowing focused ultrasound to elicit transmembrane currents through K+, Na+,
and Ca2+ channels[51, 69, 70]. I do not believe that the mechanism for fVNS is thermal in nature,
as our temperature increase is smaller than studies that show thermal effects[29, 30].
Additionally, these thermal effects on nerves have caused decreases rather than increases in
action potentials. Using a bench top system, our temperature increased on average 2°C during the
5-minute stimulation period. Studies have shown up to 8°C changes that did not cause injury to
tissue[71]. In addition, our histology samples did not indicate any damage to the nerve. However,
to reduce the temperature effects, which could lead to possible side effects even without tissue
damage, it would be worthwhile to investigate shortening the application time for treatment.
In our studies, I identified three outliers in the f3VNS group. I resuscitated two of these
three animals during the experiment, which would contribute to high levels of pro-inflammatory
cytokines. However, the third had no notable differences during the experiment. A recent study
by Downs and colleagues showed a varying success rate with stimulation of in vivo sciatic
nerves depending on the stimulation parameters[72]. Therefore, without optimized parameters,
we cannot expect to always successfully activate the vagus nerve. Furthermore, Tyler observed
that focused ultrasound only stimulated 30% of the neurons in his field, giving a possible
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indication that the kinetic state of the neuron’s ion channels could influence focused ultrasound’s
effects[69]. This is consistent with other studies where focused ultrasound and mechanosensitive
ion channels showed variation in their response to the same stimulus[69, 70, 72, 73]. We need to
perform an additional set of experiments to optimize the stimulation parameters.

4.4

Vagus Nerve Stimulation for Inflammation Control
The f1VNS and eVNS groups presented with similar reductions in serum TNF-α levels.

While both on average had lower TNF-α levels, they also showed a wide spread in the degree to
which they decreased. Previous studies often rely on an afferent vagotomy or afferent blocking
to decrease the variability in electrical stimulation results. Without any other manipulation to the
nerve, we achieved a consistent, significant decrease in serum TNF-α levels by applying focused
ultrasound multiple times during the experiment. It’s possible that we needed multiple
applications of fVNS since TNF-α levels are still rising at 120 minutes when we apply our
second therapy. This extra application of therapy may ensure the continued decrease of the
production of TNF-α in the spleen. The timing of applications necessary to suppress TNF-α
during a chronic increase in cytokines compared to an acute increase should be studied.
Many other groups use IV rather than IP injections of LPS in order to decrease the
variation in cytokine levels. However, I argue that the creation of an inflammatory response due
to the injection of LPS in the IP cavity is more physiologically and clinically relevant than an
injection into the bloodstream, as infections do not typically originate in the bloodstream. Even
with the increased variation, f3VNS statistically reduced the TNF-α levels. Experiments could be
improved by using less variable anesthesia, as depth of anesthesia changes the effectiveness of
LIFU and could increase variation[74]. We did not use isoflurane as it is known to impact nerve
conduction[75]. In addition, our methods allow us to look at the full time course of the cytokines
for each animal, which is not presented in many similar studies[64, 65]. This way, we know that
our therapy is not just delaying the TNF-α increase. In addition, it’s possible to have variable
LPS absorption, adding variation when only collecting data at a single time.
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4.5

Surgical Improvements
Over the time we did these experiments, Somann, Bayer, and I worked to improve the

methodologies of the surgical methods. We began by doing only six blood collections
(lengthening from 4 collections done previously in our lab), but increased to twelve blood
collections for the final experiments to see the entire TNF-α curve. At the beginning of the
experiments, Bayer and I used leg puncture to collect blood. However, we found this method
difficult, especially for the last two collections and occasionally obtained small plasma volumes
(~20 µL). From this, we transitioned to using catheters to collect blood, which was especially
vital for experiments involving multiple ultrasound stimulations, as I left the transducer set-up
until I performed the final stimulation. However, we had to manage many time-sensitive tasks
including: flushing the catheter, giving ket/xyl updates, taking blood collections, and applying
stimulation. Spearheaded by Somann, we brought up the Culex Automatic Blood Samplers,
which he previously used for his chronic experiments, to use on the bench top. With Robyn
McCain’s and Norvin Brun’s assistance, we set-up two side-by-side bench top systems. The
Culex Automatic Blood Samplers automatically collect blood and flush the catheter, ensuring
equal volumes of blood for each sample and that the catheter wouldn’t clot. It also increased the
accuracy of our timing, as the timer is built-in to the system.
In addition to the blood collection, we changed the ways of measuring the LPS. At first, I
used a scale to measure out LPS into eppendorf tubes before each surgery. In addition to being
time consuming, I was measuring small volumes, and the texture of LPS is difficult to work with.
Instead, with Jennifer Sturgis’s help, we pre-mixed a new bottle of LPS with saline, sonicating to
ensure it was well mixed. Then, we aliquoted the mixed LPS into eppendorf tubes and froze for
later use. Before using, we ensured the LPS was thawed and sonicated for at least 30 minutes.
I performed all of the nerve cuffing and isolation surgeries and trained Somann to place
catheters. In this way, we staggered the animals to be the most time efficient, typically
performing two animal experiments at a time. After the first exploratory ultrasound surgeries,
Bayer and I mounted the ultrasound over the animal, but were unsure of exactly where it was
focusing. Thus, we worked with David McMillan to design the positioning rod that we went on
to be used for all of the ultrasound experiments. Additionally, I worked to degas the water and
find the best way to get all of the air out of the transducer’s coupling cone.
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4.6

Future Work
Future studies include investigating both the mechanisms and the chronic potential of

fVNS therapy. First, this study needs to be replicated non-invasively in rats using ultrasound
imaging to detect the carotid and vagus nerve. To compare results to recent findings of efferent
fiber damage with VNS, the presence of fluorogold transport should be confirmed following the
application of fVNS. Additionally, we also need to characterize side effects of fVNS, including
activation of the laryngeal muscles.
Ideally, fVNS would be assessed on non-anesthetized animals, to eliminate the influences
of anesthetics[74]. However, this would likely require the use of larger animals such as rabbits or
pigs because of the size of the ultrasound transducer. Determining the intensity to use on larger
animals will be important, as there was a large difference seen in intensities needed to cause
activation between species[66, 67, 76]. However, concurrently to these studies, Bayer developed
a small, wearable transducer that could reduce the animal size necessary to perform these
studies[77].
With the ability to attenuate serum TNF-α levels in the blood, I see fVNS as a promising
alternative therapy for people with TRD. With the single application of fVNS showing similar
reductions to eVNS, I believe it could be as effective as eVNS. In addition, since critically ill or
elderly patients are not good candidates for surgery, fVNS could provide an alternative way to
relieve symptoms[78]. Although the system used in this research study is realistically too
laborious to carry around, with Bayer’s affordable, wearable transducer could be used to apply
focused ultrasound to the vagus nerve[77]. Using her transducer, it may be possible to eliminate
the many visits to the hospital or doctor’s office required by other TRD alternative treatments
such as ECT or rTMS. Finally, the non-invasive nature of focused ultrasound therapy will reduce
risks and costs associated with traditional eVNS therapy. With optimization of therapy
parameters and characterization of side effects, I believe this therapy could provide people the
option to choose a non-invasive, non-pharmaceutical treatment for their TRD.
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5. CONCLUSION

TRD is a large and growing problem, affect over 15% of the 300 million people globally
that have depression. In these studies, I investigated the use of focused ultrasound for
treatment-resistant depression by seeing its effect on serum cytokine levels. After
performing surgery to isolate the vagus nerve and injecting LPS IP to cause an inflammatory
response, multiple 5-minute stimulations counteracted the effects of LPS. I used MATLAB
to analyze the serum TNF-α levels, and I observed a statistical decrease in serum TNF-α
levels 2 hours after the LPS injection compared to the control that did not receive
stimulation. With a single 5-minute application of focused ultrasound, we saw similar
decreases in serum TNF-α levels to 5-minute electrical vagus nerve stimulation. We
observed no evidence of damage to the vagus nerve during stimulation. In the future, we
need to optimize the stimulation parameters, investigate side effects of stimulation, and
better characterize the mechanisms by which focused ultrasound of the vagus nerve reduced
serum TNF-α levels.
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